Valuation : Geron Corporation

Market Cap 97Cr 84Cr 78Cr 72Cr 134.79Cr 9.27TCr 135.22Cr 929.92Cr 362.82Cr 4.68TCr 364.24Cr 356.31Cr 16TCr P/E 2026 *
-36x
P/E 2027 * 22.2x
Enterprise Value 97Cr 84Cr 78Cr 72Cr 134.79Cr 9.27TCr 135.22Cr 929.92Cr 362.82Cr 4.68TCr 364.24Cr 356.31Cr 16TCr EV / Sales 2026 *
4.11x
EV / Sales 2027 * 2.84x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-1.31%
1 week-0.66%
Current month+17.05%
1 month+12.69%
3 months+20.80%
6 months-2.58%
Current year+14.39%
1 week 1.49
Extreme 1.49
1.59
1 month 1.24
Extreme 1.24
1.65
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Free

Director

6,103 0.0010%
20/05/26 Free

Director

2,20,000 0.0343%
20/05/26 Free

Director

2,20,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-1.31%-0.66%+7.86%-36.55% 97Cr
-1.59%-3.35%+52.37%+91.62% 6.95TCr
-1.34%-0.75%+48.21%+92.23% 6.5TCr
-5.39%-1.40%+33.19%+8.54% 2.65TCr
-2.35%-5.75%-12.90%+436.87% 2.59TCr
-8.37%-12.43%+2.08%-18.39% 2.56TCr
-0.96%+10.36%+283.06%+429.04% 2.02TCr
-0.51%+0.23%+35.77%-19.61% 2TCr
-5.38%-6.92%+0.16%+536.34% 1.57TCr
-1.47%+0.68%+45.51%+142.00% 1.35TCr
Average -2.87%-1.80%+49.53%+166.21% 2.83TCr
Weighted average by Cap. -2.65%-1.50%+51.03%+148.48%

Financials

2026 *2027 *
Net sales 24Cr 20Cr 19Cr 17Cr 33Cr 2.26TCr 33Cr 226.48Cr 88Cr 1.14TCr 89Cr 87Cr 3.78TCr 34Cr 29Cr 28Cr 25Cr 48Cr 3.27TCr 48Cr 327.79Cr 127.89Cr 1.65TCr 128.39Cr 125.6Cr 5.47TCr
Net income -2.72Cr -2.34Cr -2.2Cr -2Cr -3.78Cr -259.78Cr -3.79Cr -26Cr -10Cr -131.14Cr -10Cr -9.98Cr -434.83Cr 5.01Cr 4.32Cr 4.05Cr 3.7Cr 6.97Cr 479.24Cr 6.99Cr 48Cr 19Cr 241.92Cr 19Cr 18Cr 802.17Cr
Net Debt - -
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
28/26/28 $1.510 -1.31% 74,16,982
27/26/27 $1.530 0.00% 78,83,188
26/26/26 $1.530 -1.29% 91,23,636
25/26/25 $1.550 +1.97% 98,43,888
24/26/24 $1.520 0.00% 1,31,09,416
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.510USD
Average target price
4.250USD
Spread / Average Target
+181.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock